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ABSTRACT
Background. Understanding how frailty affects health-related quality of life (HRQOL) in those with chronic kidney disease
(CKD) could assist in the development of management strategies to improve outcomes for this vulnerable patient group.
This study aimed to evaluate the relationship between frailty and HRQOL in patients with CKD Stages 4 and 5 (G4–5) and
those established on haemodialysis (G5D).
Methods. Ninety participants with dialysis-dependent chronic kidney disease (CKD G4–5D) were recruited between
December 2016 and December 2017. Frailty was assessed using the Frailty Phenotype, which included assessments of
unintentional weight loss, weakness (handgrip strength), slowness (walking speed), physical activity and self-perceived
exhaustion. HRQOL was assessed using the RAND 36-Item Health Survey Version 1.0 (SF-36).
Results. Nineteen (21%) patients were categorized as frail. Frailty, when adjusted for age, gender, dialysis dependence and
comorbidity, had a significant effect on five of the eight SF-36 domains: physical functioning, role limitations due to
emotional problems, energy/fatigue, social functioning and pain. Regression modelling best explained the variation in the
physical functioning domain (adj. R2 ¼ 0.27, P<0.001), with frailty leading to a 26-point lower score. Exhaustion was the
only Frailty Phenotype component that had a significant effect on scores across all SF-36 domains.
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Conclusions. Frailty is independently associated with worse HRQOL in patients with CKD G4–5D, with self-perceived
exhaustion being the most significant Frailty Phenotype component contributing to HRQOL. Efforts should be made to
identify frail patients with CKD so that management strategies can be offered that aim to improve morbidity, mortality and
patient-reported outcomes, including HRQOL and fatigue.
Keywords: chronic kidney disease, end-stage kidney disease, frailty, geriatric nephrology, haemodialysis, quality of life
INTRODUCTION
Frailty is the result of a sustained deterioration in multiple
physiological processes that leads to a state of increased vulner-
ability associated with disability, hospitalizations and an in-
creased mortality risk [1]. The prevalence of frailty is markedly
higher in those with chronic kidney disease (CKD) than in the
general older population [2, 3]. The trajectory from robustness
to frailty is associated with progressive renal impairment, with
significant muscle wasting, a major contributor to physical
frailty in CKD patients, occurring prior to the commencement of
dialysis [4–6]. Importantly, frailty is an independent risk
factor for falls, hospitalization and death in those with CKD
[2, 4, 7–14].
Irrespective of frailty status, patients with CKD have a con-
siderable symptom burden, high health care utilization and
poor health-related quality of life (HRQOL) [15–18]. Although
frailty is linked with worse HRQOL in the general older popula-
tion, the relationship between frailty and HRQOL is less certain
in those with CKD [19]. The Frailty Phenotype is an operational-
ized definition of the construct of frailty and has been well stud-
ied in CKD cohorts [1, 2]. It is a composite measure that involves
five distinct components, including assessments of uninten-
tional weight loss, weakness, slowness, physical activity and
exhaustion. The relative significance of these individual compo-
nents on HRQOL in patients with CKD is not known.
Understanding how frailty and its components affect HRQOL in
those with CKD could assist in the development of targeted
management strategies to improve outcomes for this vulnera-
ble patient group.
The purpose of this study was to (i) evaluate the relationship
between frailty, categorized by the Frailty Phenotype, and
HRQOL and (ii) assess the relative significance of individual
components of the Frailty Phenotype on HRQOL in patients with
CKD Stages 4 and 5 (G4–5) and those established on haemodialy-
sis (G5D).
MATERIALS ANDMETHODS
Study design and participant selection
This was a secondary analysis of data from the Frailty
Assessment in Chronic Kidney Disease study that evaluated the
diagnostic accuracy of frailty screening methods in a cohort of
patients with advanced CKD [20]. Participants were recruited
from nephrology outpatient clinics and two haemodialysis units
at Lancashire Teaching Hospitals National Health Service (NHS)
Foundation Trust between December 2016 and December 2017.
Patients 18 years of age with CKD G4–5D were eligible for par-
ticipation in the study. Exclusion criteria included patients who
had a lower limb amputation, metastatic carcinoma, unstable
angina or who had been diagnosed in the preceding 3 months
with a myocardial infarction, transient ischaemic attack or
stroke. Written informed consent was obtained for all partici-
pants. Ethical approval was obtained from the NHS Health
Research Authority (IRAS ID 216379) and the study was con-
ducted in accordance with the Declaration of Helsinki.
Data collection
Baseline demographic and clinical characteristics data were col-
lected from medical records and during the participant inter-
view and assessment. These data included age, height, weight,
comorbidities, medication history, smoking history, blood pres-
sure, falls history and laboratory variables.
A Charlson Comorbidity Index (CCI) score was calculated for
all participants [21]. The CCI is a commonly used assessment of
comorbidity that is predictive of outcomes in CKD populations
[22–24].
A Karnofsky Performance Status Scale assessment, provid-
ing a measure of perceived performance that has been well-
studied in CKD cohorts, was performed on all participants by a
clinician [25, 26].
The Mini Mental State Examination (MMSE), a widely used
screening tool for cognitive impairment, was performed on all
participants [27, 28]. A cut-off 27 has a higher sensitivity for
identifying cognitive impairment in symptomatic populations
than the conventional cut-off of <24 [27].
All participants completed the Seniors in the Community:
Risk Evaluation for Eating and Nutrition Index (SCREEN I), which
is a validated nutritional risk screening tool for community-
dwelling older adults [29, 30]. A score 50 has been suggested to
identify individuals at nutritional risk [30].
Frailty was assessed using the Frailty Phenotype, which in-
cluded assessments of unintentional weight loss, weakness
(hand grip strength), slowness (walking speed), physical activity
and self-perceived exhaustion. Frailty was diagnosed if three or
more Frailty Phenotype components were present [1]:
1. The unintentional weight loss component was defined as a
loss of 10 pounds or 5% body weight over the preceding
12 months [1].
2. Hand grip strength (Takei 5101 GRIP-D dynamometer, Takei
Scientific Instruments Co., Niigata, Japan) was assessed in
the seated position with the elbow positioned at 90 degrees,
supported by the arm of a chair and the dynamometer sup-
ported by the assessor [31]. Both arms were examined, with
the highest score from three efforts from each side being
used for analysis. The body mass index and gender-stratified
hand grip strength cut-offs proposed by the original Frailty
Phenotype were used to describe weakness [1].
3. Walking speed was assessed by asking participants to walk
15 ft (4.57 m) at their normal walking pace on two occasions.
Participants were advised to use their walking aid, if they
normally used one. Infrared timing gates (Brower Timing
System 2012, Brower Timing Systems, Draper, UT, USA) were
used to record walking time. The fastest of two trials was
used for analysis. Participants physically unable to complete
the assessment were assigned the slowest time from within
the cohort. The height- and gender-stratified walking speed
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cut-offs suggested by the original Frailty Phenotype were
used to describe slowness [1].
4. Physical activity was assessed using a modified version of
the Minnesota Leisure Time Questionnaire [32]. Low physi-
cal activity was defined as <383 kcal/week for men and <270
kcal/week for women [1].
5. Participants were read two statements from the Center for
Epidemiological Studies Depression Scale to assess self-
perceived exhaustion: (i) I felt that everything I did was an
effort and (ii) I could not get going [33]. Participants were
then asked, ‘How often did you feel this way?’ and were pro-
vided the following scale: 0 ¼ rarely or none of the time, 1 ¼
some of the time, 2 ¼ moderate amount of the time, 3 ¼
most of the time. Self-perceived exhaustion was described if
an answer 2 was given for either statement [1].
HRQOL was assessed using the RAND 36-Item Health Survey
Version 1.0 (SF-36), which is validated in general and CKD popu-
lations [34–38]. The SF-36 consists of 36 questions and assesses
8 domains of HRQOL: physical functioning, role limitations due
to physical problems, role limitations due to emotional prob-
lems, emotional well-being, social functioning, energy/fatigue,
pain and general health perceptions [34]. The answers to desig-
nated questions are transformed to create scores for HRQOL
Table 1. Participant baseline demographic and clinical characteristics data
Characteristics
Overall
(n¼ 90)
Non-frail
(n¼ 71)
Frail
(n¼ 19)
Age (years) 696 13 686 13 736 11
Female, n (%) 45 (50) 30 (42) 15 (79)
BMI (kg/m2) 296 6 296 6 286 6
CKD Stage
CKD G4-5, n (%) 60 (67) 51 (72) 9 (47)
CKD G5D, n (%) 30 (33) 20 (28) 10 (53)
CCI, median (IQR) 3 (2) 3 (2) 4 (4)
Diabetes mellitus, n (%) 24 (27) 16 (23) 8 (42)
Karnofsky score, median (IQR) 70 (30) 80 (20) 60 (20)
Medications 96 4 86 3 116 5
Current or ex-smoker, n (%) 49 (54) 40 (56) 9 (47)
MMSE score 27a, n (%) 18 (20) 13 (19) 5 (29)
Fall within last 6 months, n (%) 16 (18) 11 (15) 5 (26)
SCREEN I score 50, n (%) 70 (78) 53 (75) 17 (89)
Blood pressure (mmHg)
Systolic 1486 20 1486 19 1496 25
Diastolic 726 14 746 14 676 15
Laboratory variables
Haemoglobin (g/L) 116.36 13.3 117.66 12.7 111.46 14.6
White cell count (109/L) 7.76 2.5 7.66 2.5 8.06 2.6
CRPb (mg/L), median (IQR) 5.3 (10.0) 5.0 (10.7) 5.5 (8.4)
Albumin (g/L) 40.96 3.3 41.36 3.3 39.66 3.3
Total protein (g/L) 67.46 5.6 67.76 5.3 66.26 6.6
Data presented as mean 6 standard deviation unless otherwise specified.. aMMSE data were available for 87 participants.. bCRP data were available for 64 participants..
BMI, body mass index; CRP, C-reactive protein; IQR, interquartile range.
FIGURE 1: Prevalence of Frailty Phenotype components.
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domains. The domain scores range from 0 to 100, with lower
scores indicating worse HRQOL [34, 35]. The SF-36 also asks
‘Compared to one year ago, how would you rate your health in
general now?’ Participants answer on a 1–5 scale, with 1 being
‘much better now than one year ago’ and 5 being ‘much worse
now than one year ago’.
Statistical analysis
As a secondary analysis, no prospective sample size calculation
was performed for the outcomes reported. Descriptive statistics
were used to summarize demographic and clinical characteris-
tics data. Pearson’s (for continuous data) or Spearman’s correla-
tion (for ordinal data) was used to assess the correlation
between SF-36 domain scores and Frailty Phenotype score, age
and CCI score. Multiple linear regression was used to assess the
magnitude of the association between frailty and SF-36 domain
scores, adjusting for age, gender, dialysis-dependence and CCI
scores, as well as the magnitude of the association between
Frailty Phenotype components and SF-36 domain scores. A P-
value <0.05 was considered statistically significant. All statisti-
cal analyses were performed on SPSS statistical software (ver-
sion 24; IBM, Armonk, NY, USA).
RESULTS
Ninety participants completed the Frailty Phenotype assess-
ment. Table 1 demonstrates the demographics and clinical
characteristics of the overall cohort and of non-frail and frail
participants. Nineteen (21%) participants were categorized as
frail. Figure 1 illustrates the prevalence of Frailty Phenotype
components.
Participant characteristics and HRQOL
Mean SF-36 scores divided by frailty status, Frailty Phenotype
components, age <65 or 65 years, gender and dialysis-
dependence are shown in Table 2. Frail participants had signifi-
cantly lower mean SF-36 scores in the following domains: phys-
ical functioning, role limitations due to physical health, energy/
fatigue, social functioning and pain. Participants categorized as
weak or slow also had significantly lower scores in these SF-36
domains. In addition to these domains, participants with low
physical activity had significantly lower scores in the role limi-
tations due to emotional problems domain. Those categorized
as suffering from exhaustion had significantly lower scores
across all SF-36 domains, whereas there was no significant
difference in the mean SF-36 domain scores for participants
who reached the unintentional weight loss threshold. Only par-
ticipants categorized as weak had significantly higher (worse)
median scores for the question regarding health change.
Participants <65 years of age had significantly lower SF-36
scores in the following domains: role limitations due to emo-
tional problems, energy/fatigue and general health. Female par-
ticipants had significantly lower scores in the physical
functioning and energy/fatigue SF-36 domains. Participants
Table 2. SF-36 scores divided by frailty status, Frailty Phenotype component, age (< or 65years), gender and dialysis dependence
Physical
functioning
Role limitations
due to physical
health
Role limitations
due to emotional
problems
Energy/
fatigue
Emotional
well-being
Social
functioning Pain
General
health
Change in
health
Frail status
Non-frail 58.16 29.5 45.5643.9 63.4640.7 47.66 22.5 74.8619.5 74.36 29.6 68.76 26.8 28.9618.6 3.0 (1.0)
Frail 22.96 21.7* 21.16 28.0** 45.6650.0 27.1617.1* 67.9624.8 52.0631.5** 39.26 27.1* 27.6619.0 4.0 (2.0)
Weight loss
Non-frail 52.46 31.4 41.4643.0 59.8642.5 44.26 23.4 74.1620.7 69.66 31.5 63.36 29.0 30.0618.3 3.0 (1.0)
Frail 30.76 25.7 28.6630.4 57.1653.5 32.96 14.4 64.1621.1 69.66 29.6 52.56 33.7 35.7620.9 3.0 (2.0)
Weakness
Non-frail 63.86 28.1 49.5643.1 64.5643.1 48.76 24.5 73.7621.9 76.36 31.7 69.46 28.1 27.0618.4 3.0 (1.0)
Frail 36.36 28.6* 30.4639.2*** 54.3643.0 37.36 19.9*** 73.0619.8 62.26 29.3*** 54.9629.1*** 30.3618.8 4.0 (1.0**)
Slowness
Non-frail 58.16 29.3 45.5643.5 61.0642.2 48.06 22.1 75.2619.3 73.46 30.0 70.16 25.7 29.5618.3 3.0 (2.0)
Frail 22.96 22.3* 21.16 30.3** 54.3647.4 25.5617.2* 66.7625.0 55.36 32.6*** 33.96 24.2* 25.3619.5 4.0 (1.0)
Physical activity
Non-frail 59.26 29.3 47.4644.1 69.0638.42 51.56 21.2 76.0618.7 78.06 28.0 68.16 26.8 30.8631.3 3.0 (1.3)
Frail 35.36 29.6* 27.6635.5*** 42.76 46.6** 28.4618.5* 68.6623.6 54.36 31.4* 52.36 31.3** 24.7615.9 4.0 (1.8)
Exhaustion
Non-frail 65.76 30.0 54.5642.4 76.9633.4 56.46 17.0 79.8615.7 81.76 26.3 78.16 19.7 32.1618.7 3.0 (1.0)
Frail 30.26 25.0* 21.16 33.7* 36.06 44.1* 25.3617.3* 64.56 23.7* 53.06 30.1* 41.16 26.8* 23.86 17.4*** 3.5 (2.0)
Age
<65 years 49.86 30.9 35.2642.3 43.2646.1 33.16 24.8 67.4625.1 57.46 36.1 56.96 32.4 21.3614.7 3.0 (2.0)
65 years 51.16 31.9 42.6642.2 66.76 40.2*** 47.66 20.9*** 75.9618.3 74.86 27.6 64.96 27.8 31.76 19.2** 3.0 (1.0)
Gender
Male 60.36 29.7 45.0642.5 57.8643.5 48.66 21.7 74.8621.0 74.46 27.8 66.36 27.5 31.4620.2 3.0 (1.5)
Female 41.16 30.4** 35.7641.8 61.5643.2 38.06 23.2*** 72.0621.0 64.76 34.0 58.76 30.9 25.8616.4 3.0 (1.5)
CKD Stage
CKD G4-5 58.56 29.9 44.3642.5 62.8642.6 44.96 22.7 74.4620.8 72.76 31.2 64.86 28.3 29.5619.7 3.0 (1.0)
CKD G5D 35.16 28.8* 32.8641.1 53.3644.3 40.06 23.5 71.3621.1 63.36 31.0 58.06 31.3 26.9616.1 2.0 (1.0)
Data presented as mean6SD or median (IQR).
*P < 0.001; . **P<0.01;. ***P<0.05.
SD, standard deviation; IQR, interquartile range.
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receiving dialysis had significantly lower scores in only the
physical functioning SF-36 domain.
Correlation between HRQOL and frailty, age and
comorbidity
Table 3 demonstrates the correlation between SF-36 domains
and Frailty Phenotype score, age and CCI score. There was a sig-
nificant negative correlation between all domain scores of the
SF-36, except the general health domain, and Frailty Phenotype
score. The correlation coefficients indicated a strong association
between the physical functioning and energy/fatigue domain
scores and the Frailty Phenotype score. There was a moderate
association between the social functioning and pain domain
scores and the Frailty Phenotype score. There was a significant
positive correlation, though the coefficients revealed a weak as-
sociation, between age and the following domain scores: role
limitations due to emotional problems, emotional well-being,
social functioning and general health. There was a significant
negative correlation between CCI score and the SF-36 pain do-
main score; again, this coefficient suggested only a weak
association.
Influence of frailty on HRQOL
Regression analyses assessing the magnitude of the association
between frailty and SF-36 domains are presented in Table 4.
Frailty, when adjusted for age, gender, dialysis-dependence and
CCI score, had a significant effect on the following SF-36
domains: physical functioning, role limitations due to emo-
tional problems, energy/fatigue, social functioning and pain.
Regression modelling best explained the variation in the physi-
cal functioning domain score, with frailty leading to a 26-point
lower score.
Regression analyses assessing the magnitude of the associa-
tion between Frailty Phenotype components and SF-36 domains
are displayed in Table 5. Self-perceived exhaustion was the only
Frailty Phenotype component that had a significant effect on
scores across all SF-36 domains. Unintentional weight loss did
not have a significant effect on any of the SF-36 domain scores.
Low physical activity had significant effects on physical func-
tioning, role limitations due to emotional problems, energy/fa-
tigue and social functioning domains. Weakness had a
significant effect on the physical functioning and general health
domains, whereas slowness had a significant effect on only the
pain domain.
DISCUSSION
To our knowledge, this is the first study that explores the rela-
tionship between frailty, as categorized by the original Frailty
Phenotype, and HRQOL in those with CKD G4–5 and CKD G5D.
Furthermore, it is the first study that assesses the relative sig-
nificance of individual Frailty Phenotype components on
HRQOL in this distinct patient group. Studies by Mansur et al.
[13] and Lee et al. [14] have demonstrated that frailty is associ-
ated with worse HRQOL in those with CKD. However, both stud-
ies used a modified version of the Frailty Phenotype to
categorize frailty, replacing objective measures of grip strength
and walking speed with a self-report assessment of physical
function. Such an approach has been shown to substantially
overestimate the prevalence of frailty [39]. Furthermore, the
self-report assessment used was the physical functioning do-
main of the SF-36, which was also used within the assessmentT
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of HRQOL [13, 14, 35] Additionally, the ‘vitality domain’ of the
SF-36 was used to determine the exhaustion component of their
modified Frailty Phenotype [13, 14, 35]. Therefore it is difficult to
interpret the findings, given the overlap of the frailty and
HRQOL assessments. Iyasere et al. [40] demonstrated that frailty
was associated with worse HRQOL, symptom burden and de-
pression scores in those with dialysis-dependent CKD. Their
study used the Clinical Frailty Scale that relies upon a health
care professional’s assessment of frailty based upon descriptors
of levels of frailty [41]. Although not as well studied as the
Frailty Phenotype in CKD populations, the Clinical Frailty Scale
has been shown to be an accurate screening tool for frailty (cat-
egorized by the Frailty Phenotype) [20] and predictive of mortal-
ity in patients with CKD [24, 42].
Our study confirms that frailty is significantly associated
with worse HRQOL in patients with CKD G4–5D. Frailty
Phenotype scores correlated with seven of the eight domains of
the SF-36. Frail participants had significantly lower mean scores
across five of the eight domains, specifically physical function-
ing, role limitations due to physical health, energy/fatigue, so-
cial functioning and pain domains. When adjusted for age,
gender, dialysis-dependence and CCI, frailty was independently
associated with at least a 20-point lower score in physical
functioning, role limitations due to emotional problems, en-
ergy/fatigue, social functioning and pain SF-36 domains.
Notably, when adjusting for frailty, the burden of comorbidity
had no effect on SF-36 scores. Older age was not associated with
worse HRQOL; in fact, older age was associated with a modest
improvement in several SF-36 domains. This relationship has
been reported previously and is perhaps due to changes in emo-
tional regulation with age [43–45]. Female participants had
worse HRQOL, specifically in physical functioning and energy/
fatigue domains, a finding that has been reported elsewhere in
the literature [43, 46, 47]. However, there was no significant ef-
fect noted within the regression model that included frailty.
Frailty was an independent predictor of poor HRQOL in this ad-
vanced CKD cohort, highlighting the importance of the con-
struct of frailty, over and above more traditional predictors of
HRQOL [43], and emphasizing the importance of frailty screen-
ing in advanced CKD populations.
Participants categorized as exhausted, regardless of whether
they were classified as frail overall, had lower mean scores
across all SF-36 domains. Depending on the SF-36 domain, the
exhaustion Frailty Phenotype component was associated with
10- to 46-point lower scores. Studies within the general older
population have also found that this domain has the greatest
Table 4. Regression analyses assessing the influence of frailty, age, gender, dialysis-dependence and comorbidity on SF-36 domains
SF-36 domain
Unstandardized
b coefficient (95% CI)
Standardized
b coefficient P-value
Physical functioning (adj. R2 ¼ 0.27, P < 0.001)
Frail 25.75 (41.19 to 10.32) 0.34 0.001
Age 0.05 (0.51–0.41) 0.02 0.82
Female 10.01 (22.06–2.04) 0.16 0.1
Dialysis 17.49 (30.29 to 4.69) 0.26 0.01
CCI 1.71 (5.95–2.53) 0.08 0.42
Role limitations due to physical health (adj. R2 ¼ 0.04, P ¼ 0.13) – – –
Role limitations due to emotional problems (adj. R2 ¼ 0.10, P ¼ 0.02)
Frail 28.74 (52.24 to 5.23) 0.27 0.02
Age 1.05 (0.35–1.75) 0.32 0.004
Female 9.59 (8.75–27.94) 0.11 0.3
Dialysis 0.22 (19.26–19.71) 0.002 0.98
CCI 2.46 (3.99–8.92) 0.08 0.45
Energy/fatigue (adj. R2 ¼ 0.16, P ¼ 0.001)
Frail 20.28 (32.33 to 8.22) 0.36 0.001
Age 0.46 (0.10–0.82) 0.26 0.01
Female 6.90 (16.31–2.51) 0.15 0.15
Dialysis 2.35 (7.64–12.34) 0.05 0.64
CCI 0.97 (4.28–2.34) 0.06 0.56
Emotional well-being (adj. R2 ¼ 0.05, P ¼ 0.09) – – –
Social functioning (adj. R2 ¼ 0.14, P ¼ 0.004)
Frail 23.41 (40.07 to 6.74) 0.31 0.01
Age 0.75 (0.25–1.24) 0.31 0.003
Female 5.31 (18.32–7.70) 0.09 0.42
Dialysis 0.36 (14.17–13.46) 0.01 0.96
CCI 1.21 (5.79–3.37) 0.05 0.6
Pain (adj. R2 ¼ 0.18, P ¼ 0.001)
Frail 28.08 (43.33 to 12.83) 0.39 <0.001
Age 0.40 (0.06–0.85) 0.18 0.09
Female 2.02 (13.93–9.88) 0.04 0.74
Dialysis 0.16 (12.81–12.48) 0.003 0.98
CCI 3.82 (8.01–0.37) 0.18 0.07
General health (adj. R2 ¼ 0.02, P ¼ 0.23) – – –
Adj. R2, adjusted R2.
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effect on HRQOL [47, 48]. Exhaustion, also known as fatigue, is a
commonly reported and especially problematic symptom in
patients with advanced CKD, particularly for those receiving di-
alysis [49–51]. Fatigue is not only associated with worse HRQOL,
but also survival in advanced CKD, with the Impact of Fatigue
on Outcomes in the Hemodialysis (HEMO) Study demonstrating
that an increase of 10 points in ‘vitality score’ was associated
with a 10% increase in mean survival [52, 53]. Accordingly,
addressing the causes of fatigue may be associated with im-
proved HRQOL and survival in non-frail and frail patients alike.
This is a challenging undertaking, as fatigue is a complex
multidimensional and multifactorial issue [50]. Appropriate
management of renal anaemia, adequate nutrition and prompt
management of concurrent medical problems is essential [50].
However, there is also an association between fatigue and psy-
chological distress; therefore, therapies that address mood and
anxiety issues may also be associated with an improvement in
fatigue symptoms [50, 54]. Sleep disorders are common in those
with advanced CKD [55]. Cognitive behavioural therapy leads to
improved sleep quality and reduced fatigue, thus it may be a
useful therapy for frail patients with CKD [56]. Furthermore, low
physical activity levels are associated with increased levels of
Table 5. Regression analyses assessing the influence of Frailty Phenotype components on SF-36 domains
SF-36 domain
Unstandardized
b coefficient (95% CI)
Standardized
b coefficient P-value
Physical functioning (adj. R2 ¼ 0.40, P < 0.001)
Weight loss frail 3.55 (24.00–16.90) 0.03 0.73
Weakness frail 11.89 (23.41 to 0.37) 0.19 0.04
Slowness frail 12.63 (28.04–2.79) 0.17 0.11
Physical activity frail 11.76 (23.11 to 0.40) 0.18 0.04
Exhaustion frail 22.85 (34.91 to 10.79) 0.36 <0.001
Role limitations due to physical health (adj. R2 ¼ 0.13, P ¼ 0.01)
Weight loss frail 0.17 (32.93–33.28) 0.001 0.99
Weakness frail 4.82 (23.47–13.83) 0.06 0.61
Slowness frail 4.07 (29.03–20.89) 0.04 0.75
Physical activity frail 10.38 (28.76–8.01) 0.12 0.27
Exhaustion frail 27.44 (46.97 to 7.91) 0.32 0.01
Role limitations due to emotional problems (adj. R2 ¼ 0.26, P < 0.001)
Weight loss frail 0.26 (31.53–31.01) 0.002 0.99
Weakness frail 5.26 (12.35–22.87) 0.06 0.55
Slowness frail 22.88 (0.69–46.45) 0.22 0.06
Physical activity frail 21.00 (38.36 to 3.64) 0.23 0.02
Exhaustion frail 46.12 (64.56 to 27.67) 0.53 <0.001
Energy/fatigue (adj. R2 ¼ 0.54, P < 0.001)
Weight loss frail 0.07 (13.19–13.06) 0.001 0.99
Weakness frail 3.96 (3.43–11.36) 0.09 0.29
Slowness frail 4.34 (14.23–5.55) 0.08 0.39
Physical activity frail 15.56 (22.85 to 8.27) 0.33 <0.001
Exhaustion frail 27.30 (35.04 to 19.56) 0.59 <0.001
Emotional well-being (adj. R2 ¼ 0.12, P ¼ 0.01)
Weight loss frail 6.29 (22.68–10.10) 0.08 0.45
Weakness frail 7.21 (2.03–16.44) 0.17 0.12
Slowness frail 0.07 (12.29–12.43) 0.001 0.99
Physical activity frail 4.51 (13.61–4.59) 0.10 0.33
Exhaustion frail 16.56 (26.23 to 6.90) 0.40 0.001
Social functioning (Adj. R2 ¼ 0.24, P < 0.001)
Weight loss frail 10.02 (12.89–32.93) 0.09 0.39
Weakness frail 1.35 (14.26–11.56) 0.02 0.84
Slowness frail 0.87 (18.14–16.40) 0.01 0.92
Physical activity frail 16.89 (29.61 to 4.16) 0.26 0.01
Exhaustion frail 24.62 (38.14 to 11.11) 0.39 <0.001
Pain (adj. R2 ¼ 0.44, P < 0.001)
Weight loss frail 10.71 (7.69–29.10) 0.10 0.25
Weakness frail 4.64 (5.73–15.00) 0.08 0.38
Slowness frail 23.57 (37.44 to 9.71) 0.33 0.001
Physical activity frail 3.12 (13.33–7.10) 0.05 0.55
Exhaustion frail 30.41 (41.27 to 19.56) 0.52 <0.001
General health (adj. R2 ¼ 0.08, P ¼ 0.04)
Weight loss frail 11.17 (3.82–26.16) 0.16 0.14
Weakness frail 8.67 (0.23–17.12) 0.24 0.04
Slowness frail 3.73 (15.03–7.57) 0.08 0.51
Physical activity frail 4.62 (12.94–3.70) 0.12 0.27
Exhaustion frail 10.36 (19.20 to 1.52) 0.28 0.02
Adj. R2, adjusted R2.
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fatigue [57]. Exercise improves fatigue in the general population
and has been shown to improve HRQOL and fatigue in those
with advanced CKD [58–60]. Evidence suggests that exercise
training can improve physical function and HRQOL in frail older
adults [61–63]. However, studies have not targeted patients with
CKD who are pre-frail or frail, a group of patients who are typi-
cally poorly represented in interventional studies [64, 65].
Further evidence is needed on the feasibility of a rehabilitation
programme for frail patients with advanced CKD. Ultimately,
management strategies likely need to be multimodal and multi-
disciplinary, including nutritional, psychological and rehabilita-
tion components [50, 66]. Additional evaluation of the
relationship between fatigue and HRQOL in frail advanced CKD
populations is needed, particularly to assess the relative contri-
butions of physical capacity and psychological well-being.
There are acknowledged limitations of this study. First, the
cross-sectional study design does not allow for conclusions to
be made on causation. Longitudinal studies are required to as-
sess for a causal relationship between frailty and HRQOL.
Second, further investigation within more culturally diverse
populations is needed given that participants within this study
were recruited from a single-centre with a predominantly
White British population. Finally, this is a secondary analysis of
a study that was powered to assess the diagnostic accuracy of
frailty screening methods in advanced CKD; therefore, the
results presented in this analysis should be interpreted
judiciously.
Conclusions
Frailty is independently associated with worse HRQOL in
patients with CKD G4–5D. Exhaustion, or fatigue, is the most
significant Frailty Phenotype component contributing to worse
HRQOL in those with advanced CKD. Efforts should be made to
identify frail patients with CKD so that management strategies
can be offered that aim to improve morbidity, mortality and
patient-reported outcomes, including HRQOL and fatigue.
Additional study is needed to determine the most significant
contributors to fatigue in frail patients with advanced CKD so
treatment can be tailored for this vulnerable group of patients.
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